| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K C J Yuen, D B Dunge. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes, obesity & metabolism. vol 9. issue 1. 2007-04-17. PMID:17199714. |
paradoxically, gh deficient adults and those with acromegaly are both predisposed to insulin resistance, but one cannot extrapolate from these pathological conditions to determine the normal metabolic roles of gh and igf-i on glucose homeostasis. |
2007-04-17 |
2023-08-12 |
human |
| Michele A Manahan, Alan P B Dackiw, Douglas W Ball, Martha A Zeige. Unusual case of metastatic neuroendocrine tumor. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 13. issue 1. 2007-04-12. PMID:17360306. |
to report a rare case of metastatic growth hormone (gh)-secreting pituitary carcinoma causing acromegaly. |
2007-04-12 |
2023-08-12 |
Not clear |
| Moisés Mercado, Mario Galean. [Pharmacological treatment of acromegaly]. Gaceta medica de Mexico. vol 142. issue 4. 2007-04-06. PMID:17022308. |
acromegaly is an endocrine disorder usually due to a growth hormone (gh)-secreting pituitary adenoma. |
2007-04-06 |
2023-08-12 |
Not clear |
| Daniela Zylberberg, Erika C O Naliato, Alair Sarmet, Eduardo Sato, Fernando S R Costa, Alice H D Violant. [IGF-1 plasma levels evaluation in prolactinoma]. Arquivos de neuro-psiquiatria. vol 64. issue 3B. 2007-04-05. PMID:17057896. |
igf-1 (insulin-like growth factor-1) is the main responsible for gh actions and a parameter for the diagnosis of acromegaly. |
2007-04-05 |
2023-08-12 |
Not clear |
| Daniela Zylberberg, Erika C O Naliato, Alair Sarmet, Eduardo Sato, Fernando S R Costa, Alice H D Violant. [IGF-1 plasma levels evaluation in prolactinoma]. Arquivos de neuro-psiquiatria. vol 64. issue 3B. 2007-04-05. PMID:17057896. |
the prevalence of patients with gh >0.4 ng/ml and elevated igf-1 was higher than expected; however, after gtt, no patient fulfilled the diagnostic criteria for acromegaly. |
2007-04-05 |
2023-08-12 |
Not clear |
| J Lindhol. Growth hormone: historical notes. Pituitary. vol 9. issue 1. 2007-04-03. PMID:16703403. |
in the same period both gh releasing and inhibiting hormones were identified and an analogue of somatostatin had evolved into the first effective pharmacological treatment for acromegaly. |
2007-04-03 |
2023-08-12 |
human |
| Tomoko Miyoshi, Fumio Otsuka, Tomoko Kawabata, Kenichi Inagaki, Tomoyuki Mukai, Masanori Kawashima, Toshio Ogura, Masahiro Yamamura, Tetsuro Sei, Hirofumi Makin. Manifestation of rheumatoid arthritis after transsphenoidal surgery in a patient with acromegaly. Endocrine journal. vol 53. issue 5. 2007-04-02. PMID:16896264. |
here, we report a 70-year-old japanese woman with acromegaly, who complained of bilateral finger stiffness and polyarthralgia two months after transsphenoidal surgery of a growth hormone (gh)-secreting pituitary adenoma. |
2007-04-02 |
2023-08-12 |
Not clear |
| Tomoko Miyoshi, Fumio Otsuka, Tomoko Kawabata, Kenichi Inagaki, Tomoyuki Mukai, Masanori Kawashima, Toshio Ogura, Masahiro Yamamura, Tetsuro Sei, Hirofumi Makin. Manifestation of rheumatoid arthritis after transsphenoidal surgery in a patient with acromegaly. Endocrine journal. vol 53. issue 5. 2007-04-02. PMID:16896264. |
regardless of the levels of gh and igf-1, acromegaly patients frequently complain about joint-related symptoms even after remission. |
2007-04-02 |
2023-08-12 |
Not clear |
| Ippei Kanazawa, Toru Yamaguchi, Yuko Yamane, Norio Murakami, Yuzuru Kato, Toshitsugu Sugimot. Acromegaly associated with monoclonal gammopathy of undetermined significance (MGUS). Endocrine journal. vol 53. issue 5. 2007-04-02. PMID:16926522. |
the patient visited shimane university hospital for treatment of spinal canal stenosis, and was diagnosed as acromegaly with gh 43.1 ng/ml, insulin-like growth factor (igf)-i 510 ng/ml and the detection of a pituitary adenoma by mri. |
2007-04-02 |
2023-08-12 |
Not clear |
| Ippei Kanazawa, Toru Yamaguchi, Yuko Yamane, Norio Murakami, Yuzuru Kato, Toshitsugu Sugimot. Acromegaly associated with monoclonal gammopathy of undetermined significance (MGUS). Endocrine journal. vol 53. issue 5. 2007-04-02. PMID:16926522. |
we suspect a pathogenetic link between acromegaly and mgus in this case, because both gh and igf-i are known to directly promote immunoglobulin production from plasma cells, thus inducing the proliferation of the cells in vitro. |
2007-04-02 |
2023-08-12 |
Not clear |
| Jens Otto Lunde Jørgensen, Ulla Friis Feldt-Rasmussen, Marianne Andersen, Lars Østergård Kristensen, Peter Laurberg, Jørgen Week. [Acromegaly: new principles for treatment]. Ugeskrift for laeger. vol 169. issue 10. 2007-03-20. PMID:17359733. |
acromegaly is a rare condition usually caused by a gh secreting pituitary tumor. |
2007-03-20 |
2023-08-12 |
Not clear |
| I Schreiber, M Buchfelder, M Droste, K Forssmann, K Mann, B Saller, C J Strasburge. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European journal of endocrinology. vol 156. issue 1. 2007-03-07. PMID:17218728. |
treatment of acromegaly with the gh receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the german pegvisomant observational study. |
2007-03-07 |
2023-08-12 |
Not clear |
| I Schreiber, M Buchfelder, M Droste, K Forssmann, K Mann, B Saller, C J Strasburge. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European journal of endocrinology. vol 156. issue 1. 2007-03-07. PMID:17218728. |
the gh receptor antagonist pegvisomant is a highly effective new treatment option in acromegaly. |
2007-03-07 |
2023-08-12 |
Not clear |
| M Georgitsi, A Karhu, R Winqvist, T Visakorpi, K Waltering, P Vahteristo, V Launonen, L A Aaltone. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. British journal of cancer. vol 96. issue 2. 2007-03-05. PMID:17242703. |
these patients have prolactin (prl) or growth hormone (gh) oversecreting pituitary adenomas, the latter exhibiting acromegaly or gigantism. |
2007-03-05 |
2023-08-12 |
Not clear |
| T Ueland, S L Fougner, K Godang, T Schreiner, J Bollersle. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. European journal of endocrinology. vol 155. issue 5. 2007-01-08. PMID:17062887. |
serum gh and igf-i are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. |
2007-01-08 |
2023-08-12 |
Not clear |
| T Ueland, S L Fougner, K Godang, T Schreiner, J Bollersle. Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. European journal of endocrinology. vol 155. issue 5. 2007-01-08. PMID:17062887. |
acromegaly is characterized by a persistent hypersecretion of gh and provides information on long-term effects of gh on bone metabolism. |
2007-01-08 |
2023-08-12 |
Not clear |
| F Fracassi, G Gandini, A Diana, R Preziosi, T S G A M van den Ingh, P Famigli-Bergamini, H S Kooistr. Acromegaly due to a somatroph adenoma in a dog. Domestic animal endocrinology. vol 32. issue 1. 2006-12-21. PMID:16472961. |
in conclusion, this dalmatian dog with acromegaly and insulin resistance represents the first case of gh hypersecretion proven to be due to a somatotroph adenoma. |
2006-12-21 |
2023-08-12 |
dog |
| K Müssig, B Gallwitz, M B Ranke, M Horger, H U Häring, H J Quabb. Acromegaly and end-stage renal disease: a diagnostic challenge. Journal of endocrinological investigation. vol 29. issue 8. 2006-12-14. PMID:17033266. |
in the work-up for acromegaly, clinicians should be alerted to gh resistance in chronic renal failure. |
2006-12-14 |
2023-08-12 |
Not clear |
| Anat Ben-Shlomo, Shlomo Melme. Skin manifestations in acromegaly. Clinics in dermatology. vol 24. issue 4. 2006-12-13. PMID:16828406. |
cutaneous changes in acromegaly result from excess gh and igf-1 action on skin cells and adnexae. |
2006-12-13 |
2023-08-12 |
Not clear |
| Anat Ben-Shlomo, Shlomo Melme. Skin manifestations in acromegaly. Clinics in dermatology. vol 24. issue 4. 2006-12-13. PMID:16828406. |
controlling gh and igf-1 over-secretion alleviates most cutaneous manifestations of acromegaly; however, regression may be incomplete. |
2006-12-13 |
2023-08-12 |
Not clear |